Zevra Therapeutics Inc. (ZVRA)
ZVRA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/0001434647-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ZVRA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001434647 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $106.5M |
| Net income | $83.2M |
| Operating income | -$62.9M |
| Net margin | 78.2% |
| Operating margin | -59.1% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $62.4M |
| Total assets | $284.7M |
| P/E (computed) | 7.4× |
| P/S (computed) | 5.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-08-09 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-08-05 |
| Latest proxy | DEF 14A | 2026-04-20 |
Source: SEC EDGAR submissions feed, 867 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.6% |
| 1 month | -11.2% |
| 3 months | -18.9% |
| Year to date | +15.5% |
| 1 year | -3.2% |
| From 52-week high | -29.9% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| WVE | Wave Life Sciences Inc. | $3.14 | -4.27% | $618.7M |
| OLMA | Olema Pharmaceuticals Inc. | $7.02 | -4.62% | $614.2M |
| DSGN | Design Therapeutics Inc. | $9.78 | -10.36% | $612.0M |
| ABUS | Arbutus Biopharma Corporation | $4.11 | -0.96% | $630.0M |
| IRWD | Ironwood Pharmaceuticals Inc. | $3.59 | -4.52% | $593.2M |
| CLYM | Climb Bio Inc. | $10.31 | -4.80% | $592.2M |
| NVCT | Nuvectis Pharma Inc. | $18.15 | -7.82% | $591.9M |
| AVTX | Avalo Therapeutics Inc. | $12.01 | -9.29% | $644.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier